MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Positive elements include increased manufacturing capacity and potential market opportunities for EscharEx. However, challenges such as higher EBITDA losses, revenue guidance reliance on uncertain contracts, and management's lack of transparency in specific financial contributions temper optimism. The Q&A session highlights demand uncertainties and geopolitical risks, further contributing to a neutral sentiment. Without the market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral stock price movement in the short term.
Key Financial Performance
Revenue for Q4 2025 $1.9 million, compared to $5.8 million in Q4 2024, a decrease primarily driven by lower development services revenue due to the U.S. government shutdown, which delayed budget approval and the initiation of new contractual agreements.
Gross Profit for Q4 2025 $0.3 million or 14.9% of revenue, compared to $0.9 million or 15.5% in Q4 2024, reflecting the impact of lower revenue.
R&D Expenses for Q4 2025 $4.5 million, compared to $3 million in Q4 2024, reflecting continued investment in the EscharEx VALUE Phase III study.
SG&A Expenses for Q4 2025 $3.6 million, compared to $4 million in Q4 2024, mainly reflecting lower marketing and share-based compensation expenses.
Operating Loss for Q4 2025 $7.8 million, compared to $6.1 million in Q4 2024, driven by lower revenue and increased R&D expenses.
Net Loss for Q4 2025 $7.2 million or $0.56 per share, compared to $3.9 million or $0.36 per share in Q4 2024, primarily attributable to lower noncash financial income from the revaluation of warrants.
Adjusted EBITDA Loss for Q4 2025 $6.5 million, compared to $4.9 million in Q4 2024, reflecting lower revenue and higher R&D expenses.
Revenue for Full Year 2025 $17 million, compared to $20.2 million in 2024, a decrease primarily attributable to the U.S. government shutdown and lower product sales to Vericel.
Gross Profit for Full Year 2025 $3.3 million or 19.2% of revenue, compared to $2.6 million or 13% in 2024, with margin improvement reflecting a more favorable revenue mix.
R&D Expenses for Full Year 2025 $14.3 million, compared to $8.9 million in 2024, driven by investment in the EscharEx VALUE Phase III trial.
SG&A Expenses for Full Year 2025 $14.2 million, versus $13.1 million in 2024, mainly reflecting higher marketing authorization holder expenses.
Operating Loss for Full Year 2025 $25.3 million, compared to $19.4 million in 2024, driven by increased R&D and SG&A expenses.
Net Loss for Full Year 2025 $23.9 million or $2.10 per share, compared to $30.2 million or $3.03 per share in 2024, with the reduction primarily driven by $2.2 million of noncash financial income from the revaluation of warrants in 2025, compared to $10.7 million of noncash financial expenses in 2024.
Adjusted EBITDA Loss for Full Year 2025 $20.3 million, compared to $14.8 million in 2024, reflecting higher R&D and SG&A expenses.
Cash Position as of December 31, 2025 $53.6 million in cash, cash equivalents, and deposits, compared to $43.6 million at year-end 2024, reflecting a $30 million registered direct offering and $3.5 million in proceeds from Series A warrant exercises.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EscharEx Phase III VALUE trial: Enrollment ongoing for venous leg ulcers with 216 patients targeted across 40 sites in the US and Europe. Completion expected by year-end 2026.
EscharEx expansion: Phase II protocol for diabetic foot ulcers aligned with FDA and EMA, study initiation planned for H2 2026. Pressure ulcers study also expected to begin in H2 2026.
NexoBrid manufacturing facility: Expanded facility operational, increasing production capacity sixfold. Regulatory approvals expected in 2026.
NexoBrid adoption in the US: Utilization expanded to over 70 burn centers, covering most of Vericel's 90 target accounts.
Global demand for NexoBrid: Supported by real-world data and military analyses, showing clinical applicability in severe burns and trauma care.
Financial performance: 2025 revenue was $17M, down from $20.2M in 2024, due to US government shutdown and lower product sales. Gross profit improved to 19.2% of revenue.
R&D investment: Increased to $14.3M in 2025, driven by EscharEx Phase III trial.
Cash position: Ended 2025 with $53.6M in cash, supported by a $30M direct offering and $3.5M from warrant exercises.
Revenue guidance: 2026 revenue projected at $24M-$26M, 2027 at $32M-$35M, and 2028 at $50M-$55M, including potential EscharEx contributions.
National preparedness initiatives: Plans to prioritize stockpiling and collaboration with military and emergency response systems post regulatory clearance of NexoBrid facility.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Ongoing conflict with Iran: The conflict poses operational risks and challenges to MediWound's ability to maintain resilience and discipline in its operations.
Regulatory approvals for expanded manufacturing facility: The commercial availability of the expanded manufacturing facility for NexoBrid is subject to regulatory approvals, which could delay its utilization and impact revenue growth.
U.S. government shutdown: The shutdown delayed budget approval and the initiation of new contractual agreements, leading to lower development services revenue.
Increased R&D expenses: R&D expenses rose significantly due to investment in the EscharEx VALUE Phase III study, impacting the company's financials.
Lower product sales to Vericel: A decrease in product sales to Vericel contributed to a decline in overall revenue for 2025.
Net loss and operating loss: The company reported increased net and operating losses for the quarter and year, driven by lower revenue and higher expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Reaffirmed revenue guidance of $24 million to $26 million for 2026, $32 million to $35 million for 2027, and $50 million to $55 million for 2028. The 2028 outlook includes a potential initial contribution related to EscharEx, subject to regulatory approval.
EscharEx Clinical Development: Enrollment in the global Phase III VALUE study for venous leg ulcers is ongoing, with completion and interim assessment expected by year-end 2026. Expansion into diabetic foot ulcers and pressure ulcers is planned, with Phase II and investigator-initiated studies starting in the second half of 2026.
NexoBrid Manufacturing and Commercialization: Expanded manufacturing facility is operational, increasing production capacity sixfold. Regulatory approvals for commercial availability are expected in 2026. Plans to prioritize national preparedness initiatives, including stockpiling and collaboration with military and emergency response systems, following regulatory clearance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the status of the NexoBrid manufacturing expansion project and its impact on demand?
A:The expanded manufacturing facility is operational with a sixfold increase in capacity. Regulatory approvals are expected in the second half of 2026, after which products manufactured during the validation process can be released. Demand is currently larger than manufacturing capacity, but future demand post-approval is uncertain.
Q:What is the potential market size for EscharEx in the U.S. for pressure ulcers?
A:An investigator-led pressure ulcer study will start this year, along with a market research project. Pressure ulcers are considered one of the three major ulcer types, potentially representing roughly one-third of the business. However, further research is needed to determine how many pressure ulcers require debridement and are applicable to EscharEx.
Q:How much of the 2026 revenue guidance depends on new contracts with BARDA and DOW?
A:The 2026 revenue guidance includes contributions from BARDA and the Department of War (DOW). BARDA issued an RFP in August 2025, and Vericel is leading the process in the U.S. MediWound has received $18.2 million in funding from the DOW for NexoBrid development. However, specific splits of revenue contributions are not disclosed.
Q:What is the role of B. Braun in the DFU study and its significance?
A:B. Braun is one of seven collaborators in the DFU study, providing their antimicrobial wound cleanser, Prontosan, for use during dressing changes. Collaborators supply products necessary for optimal wound care, reducing variability in the study and facilitating future partnerships.
Q:What are the potential scenarios for the VLU trial's adaptive adjustment at the 65% enrollment mark?
A:The study may continue as planned with 216 patients or increase sample size to preserve 90% statistical power. If additional patients are needed, it could extend the study timeline by a few months and cost a few million dollars. The goal is to maintain statistical power and ensure successful trial completion.
Q:Is the geopolitical situation in Israel affecting the supply chain for clinical studies?
A:No significant impact is anticipated. There is sufficient EscharEx supply at sites in Europe and the U.S. to support trials for at least six months, and other necessary supplies are sourced from global companies.
Q:Why were 2025 revenues below expectations, and what is the outlook for 2026?
A:2025 revenues were $17 million, below the expected $24 million, primarily due to the U.S. government shutdown delaying budget approvals and new contracts. The 2026 revenue guidance of $24-$26 million assumes contributions from BARDA, DOW, and product sales, but specific splits are not disclosed.
Q:Why was the decision made to proceed with a Phase II DFU study instead of an adaptive Phase II/III design?
A:Feedback from the FDA and EMA indicated that a 50-patient Phase II study would be sufficient to demonstrate EscharEx's advantage in treating DFUs. Additional studies may be conducted if necessary, but the current approach allows for a stepwise progression.
Q:What is the strategic importance of the pressure ulcer study?
A:The pressure ulcer study aims to demonstrate EscharEx's efficacy in debriding pressure ulcers and to understand the market size. It is a small trial to complement data from other indications and highlight the product's potential to partners and investors.
Q:What is the status of the head-to-head study for EscharEx?
A:The head-to-head study against collagenase or other nonsurgical standards of care is planned to start mid-2026. It is intended to support market access discussions and determine EscharEx's pricing.
Q:What is the enrollment status and timeline for the VALUE study?
A:Enrollment is on track, with interim analysis and completion expected by the end of 2026. Specific enrollment numbers are not disclosed to protect study integrity.
Q:What is the expected timing for BARDA revenues in 2026?
A:BARDA revenues are expected to begin in Q2 2026, with a significant increase in revenues anticipated in the second half of the year due to manufacturing capacity expansion and BARDA contributions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific splits of revenue contributions from BARDA, DOW, and product sales for the 2026 guidance. They also did not disclose enrollment numbers or trends for the VALUE study to protect study integrity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Braun EscharEx
Coloplast ConvaTec
ConvaTec Essity
Crans Montana
Defense Forces
Department War
EMA Phase
Enrollment Phase
EscharEx approval
EscharEx development
EscharEx milestone
EscharEx term
Essity Solventum
Europe assessment
Forces combat
Full
Gaia
III VALUE
Phase II
Phase III
RD investment
Switzerland
advancement
agreement
casualty
conflict
decrease
driver
government shutdown
income revaluation
indication industry
investment VALUE
majority
marketing
noncash income
outlook
role
MDWD Transcript
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript
Unknown5-27
The earnings call summary presents a mixed outlook. The reaffirmation of revenue guidance and ongoing clinical developments are positive, but uncertainties in regulatory approvals and manufacturing expansions pose risks. The Q&A reveals potential delays and a lack of specific details on key contracts, which may cause investor concern. Overall, despite some promising developments, the lack of clarity and potential operational challenges lead to a neutral sentiment.
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents a mixed outlook. Positive elements include increased manufacturing capacity and potential market opportunities for EscharEx. However, challenges such as higher EBITDA losses, revenue guidance reliance on uncertain contracts, and management's lack of transparency in specific financial contributions temper optimism. The Q&A session highlights demand uncertainties and geopolitical risks, further contributing to a neutral sentiment. Without the market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral stock price movement in the short term.
MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call summary presents a mixed picture with both positive and negative aspects. The company shows strong partnerships and financial flexibility, but faces challenges like increased EBITDA loss and dependency on government contracts. The Q&A reveals optimism in sales estimates and market strategy but lacks transparency in revenue breakdown and contract timelines. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and financial challenges.
MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presented mixed signals. While strategic collaborations and funding are positive, the decline in revenue and increased operating loss are concerning. The Q&A highlighted ongoing projects and potential future benefits but also revealed some uncertainties, particularly regarding patient recruitment and manufacturing timelines. Despite some positive developments, the overall financial health and lack of immediate catalysts suggest a neutral market reaction.
MDWD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
